Keyphrases
Virus Latency
100%
Epstein-Barr Virus
100%
In Vivo Model
100%
LMP2A
81%
B Lymphocytes
63%
Latent Infection
36%
Signal Transduction
18%
Latent Membrane Protein 1 (LMP1)
18%
Lymphocyte Proliferation
18%
Continuous Cell Lines
9%
Expressed Protein
9%
Normal B Cells
9%
Human Host
9%
Cell Surface
9%
Malignancy
9%
Encoded Protein
9%
Cell Surface Receptor
9%
Nuclear Proteins
9%
Transgenic Mouse Model
9%
β-cell Function
9%
Lymphoblastoid Cell Lines
9%
Receptor-mediated
9%
Virus-specific
9%
Episome Maintenance
9%
Episome
9%
Virus
9%
Nasopharyngeal Carcinoma
9%
Epstein-Barr Virus Infections
9%
Burkitt Lymphoma
9%
Latently Infected
9%
Immune Suppression
9%
PCR Analysis
9%
Infectious Mononucleosis
9%
Virus B
9%
Integral Membrane Protein
9%
Latent Virus Infection
9%
AIDS Patients
9%
EBNA1
9%
Organ Transplantation
9%
Medicine and Dentistry
Virus Latency
100%
Epstein Barr Virus
100%
B Lymphocyte
63%
Infection
27%
In Vitro
27%
Lymphocyte Proliferation
18%
Episome
18%
Latent Virus Infection
18%
Signal Transduction
18%
Cell Surface Receptor
9%
Epstein-Barr Virus Infection
9%
Organ Transplantation
9%
Cell Function
9%
B Cell
9%
Lymphoblastoid Cell Line
9%
Burkitt's Lymphoma
9%
Cancer
9%
Infectious Mononucleosis
9%
Immunosuppressive Treatment
9%
Cell Surface
9%
Nasopharynx Carcinoma
9%
Nuclear Protein
9%
Cell Line
9%
Virus
9%
Membrane Protein
9%